EBVALLO

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania.

Active ingredients

The drug EBVALLO contains one active pharmaceutical ingredient (API):

1	Tabelecleucel UNII G3NJ7M8N4H - TABELECLEUCEL
	Tabelecleucel is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner. Tabelecleucel has an equivalent mechanism of action to that demonstrated by endogenous circulating T cells in the donors from which the medicinal product is derived. The T-cell receptor of each clonal population within tabelecleucel recognises an EBV peptide in complex with a specific HLA molecule on the surface of target cells (the restricting HLA allele) and allows the medicinal product to exert cytotoxic activity against the EBV-infected cells.
	Read more about Tabelecleucel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EBVALLO Dispersion for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XL09		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3040322
FI	Lääkealan turvallisuus- ja kehittämiskeskus	406554
FR	Base de données publique des médicaments	66829076
IT	Agenzia del Farmaco	050463013
LT	Valstybinė vaistų kontrolės tarnyba	1096126